

SCIENTIFIC PROGRAM

(October 5, 2026)

(The Current Sessions and Presentations are in Eastern Daylight Time and Subject to Change)

TUESDAY, OCTOBER 6, 2026

8:00AM **WELCOME AND INTRODUCTION**
Faina Shtern, MD, President and CEO, AdMeTech Foundation

8:15AM **SESSION I (PART 1): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION**

Moderators:

Peter Albers, MD, Chairman, Department of Urology, Medical Faculty, Heinrich-Heine-University Düsseldorf and Division Head, Division of Personalized Early Detection of Prostate Cancer at the German Cancer Research Center (DKFZ), Heidelberg University, Germany

Sigrid Carlsson, MD, PhD, MPH, Division Head, Clinical Epidemiology of Early Cancer Detection, German Cancer Research Center (DKFZ), Heidelberg University, Germany

Stenio Zequi, MD, MSc, PhD, Head of Referral Center for Urological Tumors, A.C. Camargo Cancer Center, Brazil

8:30AM **Topic 1: State of the Art and Future Directions in "Smart" Prostate Cancer Screening**

8:30AM *Topic 1A: Advancing Risk-Stratified Screening and Early Detection:* Sigrid Carlsson, MD, PhD, MPH

8:40AM Q & A

8:42AM *Topic 1B: Update on PROBASE Trial: Baseline PSA in Young Men (Aged 45 and 50):* Peter Albers, MD

8:52AM Q & A

8:54AM *Topic 1C: Overview and Update on ERSPC, PIAS, and PRAISE-U Clinical Trials:* Roderick C.N. van den Bergh, MD, PhD, Department of Urology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands

9:04AM *Topic 1D: Organized Prostate Testing (OPT) in Sweden:* Anders Bjartell, MD, PhD, FEBU, Professor in Urology, Department of Translational Medicine, Lund University; and Senior Consultant, Skane University Hospital, Sweden

9:14AM Q & A

9:16AM *Topic 1E: Update on TRANSFORM - National UK Trial of Prostate Cancer Screening:* Rhian Gabe, PhD, Professor of Biostatistics and Clinical Trials, Director of Barts Clinical Trials Units, Wolfson Institute of Population Health, Queen Mary University of London, United Kingdom

9:26AM Q & A

9:28AM *Topic 1F: Update on PROSCREEN: A Randomized Population-Based Screening Trial Combining PSA, Kallikrein Panel and MRI:* Anssi Auvinen, MD, PhD, Professor and Head, Department of Epidemiology, Tampere University, Finland

9:38AM Q & A

9:40AM-10:00AM *Panel Discussion: "Smart" Prostate Cancer Screening*

10:00AM-10:30AM **COFFEE BREAK**

10:30AM **SESSION I (PART 2): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION**

Moderators:

Preston Sprenkle, MD, Associate Professor of Surgery, Yale University School of Medicine; and Chair, NCCN Prostate Cancer Early Detection Panel

Clare M. C. Tempany-Afdhal, MB, BAO, BCh, Ferenc Jolesz MD Professor of Radiology, Harvard Medical School; Scientific Director of Clinical and Translational Research MGB, Director of the Ferenc Jolesz National Center for Image-Guided Therapy & AMIGO; and Immediate Past Chair, Joint American College of Radiology, AdMeTech Foundation and European Society of Urogenital Radiology Steering Committee on PI-RADS

10:30AM **Topic 2: Current and Emerging Diagnostic Tools for Improving Risk Assessment, Selection of Patients for Biopsy and Tissue Sampling**

10:30AM *Topic 2A: Current and Emerging Liquid Diagnostics*

10:30AM *Overview of Liquid Biomarkers:* E. David Crawford, MD, Professor of Urology, Department of Urology; and Jack A. Vickers Director of Prostate Cancer Research, University of California San Diego

10:40AM Q & A

10:42AM *Large-Scale, Prospective, Clinical Validation Study of the Diagnostic Performance of IsoPSA Without and In Combination with Multi-Parametric MRI for the Detection of High-Grade Prostate Cancer:* Mark Stovsky, MD, MBA, FACS, Chief Medical Officer, Cleveland Diagnostics, Inc. Sponsored by Cleveland Diagnostics.

10:48AM Q & A

10:50AM *Topic 2B: Current and Emerging Imaging Tools and Targeted Biopsies*

10:50AM *OPTIMUM Trial – A 3-Arm Randomized Controlled Clinical Study Evaluating the Role of Micro-Ultrasound in Men with Clinical Suspicion of Prostate Cancer:* Laurence Klotz, MD, Professor of Surgery, University of Toronto and Chair of Prostate Cancer Research, Sunnybrook Medical Center; and Chair, World Urologic Oncology Federation

11:00AM Q & A

11:02AM *MRI PI-RADS Standardization and Clinical Evaluation:* Clare M. C. Tempany-Afdhal, MB, BAO, BCh

11:12AM Q & A

11:14AM *Towards Reproducible Prostate MRI Across Scanners and Sites: Preliminary Clinical Evidence for Concurrent ADC Calibration Using METRION:* Xavier Golay, PhD, MS, Honorary Professor of MRI Physics, University College London, UK

11:24AM Q & A

11:26AM *Topic 2C: State of the Art and Future Directions in Prostate Biopsies*

11:26AM *Role of MRI-Targeted Biopsy in Optimizing Prostate Cancer Diagnosis:* Fergus Coakley, MD, Professor and Chair of Diagnostic Radiology, School of Medicine, Oregon Health and Science University

11:36AM Q & A

11:38AM *Topic 2D: Do Biopsies Account for Some of the Progression We See After Prostate Cancer Treatments?* Mark Emberton, MD, Professor of Interventional Oncology, Division of Surgery and Interventional Science, University College London; and Honorary Consultant Urologist, University College London Hospital, United Kingdom

11:48AM Q & A

11:50AM-12:30PM *Panel Discussion: Current and Emerging Diagnostic Tools*

12:30PM **Topic 3: Newly Identified Mutations Associated with Prostate Cancer Risk and Aggressiveness:** Brian T. Helfand, MD, PhD, Ronald L. Chez Family and Richard Melman Family Endowed Chair in Prostate Cancer, and Clinical Professor, University of Chicago, Pritzker School of Medicine, NorthShore University HealthSystem, Endeavor Health

12:40PM Q & A

12:42PM **Topic 4: NCCN Guidelines for Early Detection of Prostate Cancer:** Preston Sprenkle, MD

12:52PM Q & A

12:54PM-1:30PM **General Discussion** – Moderators and Speakers

1:30PM-2:00PM **VIP NETWORKING DISCUSSION FOR SPEAKERS AND SPONSORS (BY INVITATION ONLY)**

2:00PM-3:00PM **LUNCH BREAK**

3:00PM **KEYNOTE PRESENTATIONS**

3:00PM **NCCN Guidelines for Prostate Cancer Treatment**: Mack Roach III MD, FACR, FASTRO, FASCO, Professor of Radiation Oncology and Urology and Director, Particle Therapy Research Program & Outreach, Department of Radiation Oncology, UCSF Helen Diller Family Comprehensive Cancer Center

3:15PM Q & A

3:20PM **Precision Care and Health Disparities in Black Men:** Adam B. Murphy, MD, MBA, MSCI, Distinguished Professor of Population Health Research in Urology, Department of Urology and Preventive Medicine, Northwestern Medicine - Feinberg School of Medicine

3:35PM Q & A

3:40PM **PANEL ON BIOINFORMATICS, ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR A MULTI-MODALITY DATA ANALYSIS FOR PRECISION DIAGNOSIS AND TREATMENT**

Moderators:

Paul Boutros, PhD, MBA, Professor of Cancer Genetics & Epigenetics and Director, Cancer Center; and Vice President, Data Science & AI, Sanford Burnham Prebys Medical Discovery Institute

Amita Shukla-Dave, PhD, Vice-Chair, Radiology-Medical Physics Outreach; Deputy Service Chief for Predictive Informatics, and Director of Quantitative Imaging, Department of Radiology, Memorial Sloan Kettering Cancer Center

3:50PM *The Evolution of AI Tooling: Should I Be Scared Yet?:* Paul Boutros, PhD, MBA

4:00PM Q & A

4:02PM *Large Data: Leveraging Bioinformatics/AI Integration for Improving Prostate Cancer Care:* Matthew Rettig, MD, Professor of Medicine and Urology, and Medical Director, Prostate Cancer Program, David Geffen School of Medicine, UCLA; Chief, Division of Hematology-Oncology, VA Greater Los Angeles Healthcare System; and National Co-Chair, VA Precision Oncology Program Cancer of the Prostate (POPCaP)

4:12PM Q & A

4:14PM *AI for MR Scanning and Disease Prediction:* Angela Tong, MD, Abdominal Radiologist, Grossman School of Medicine, New York University

4:24PM Q & A

4:26PM *Racially-Associated MRI Analysis and Modeling for Predicting Aggressive Prostate Cancer*: Kyung Sung, PhD, Professor of Radiological Sciences, Magnetic Resonance Research Labs, David Geffen School of Medicine, University of California, Los Angeles

4:36PM Q & A

4:38PM *AI in Surgery and Pathology for Prostate Cancer:* Saad Nadeem, PhD, Associate Attending Computer Scientist, Department of Medical Physics, Memorial Sloan Kettering Cancer Center

4:48PM Q & A

4:50PM *AI and Multi-Modality Diagnostics for Prostate Cancer:* Francisco Sanchez-Vega, PhD, Assistant Attending, Computational Oncology Service, Department of Epidemiology and Biostatistics; and Head of Real-World Data Analysis, Halvorsen Center for Computational Oncology, Memorial Sloan Kettering Cancer Center

5:00PM Q & A

5:02PM-5:30PM *Panel Discussion: Moderators and Speakers*

5:30PM-6:00PM **GENERAL DISCUSSION**

WEDNESDAY, OCTOBER 7, 2026

8:00AM **SESSION II (PART 1): CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER**

Moderators:

Mohammed Shahait, MD, Assistant Professor of Clinical Urology, Department of Urology, University of California, Irvine

Lalitha K. Shankar, Acting Associate Director, Cancer Imaging Program; and Chief, Clinical Trials Branch, National Cancer Institute, National Institutes of Health

Steven Raman, MD, Clinical Professor of Radiology and Director of Prostate MR Imaging and Interventions, David Geffen School of Medicine, UCLA

8:05AM **Topic 1: Multiomics for Prostate Cancer**

8:05AM *Topic 1A: Prostate Cancer Imaging*

8:05AM *PRIMARY2 Clinical Trial - PSMA PET/CT as a "Manogram" to Improve Prostate Cancer Diagnosis:* Professor Michael Hofman, MBBS, FRACP, FAANMS, FICIS, FSNNMI, FAHMS, GAICD, PET/CT Head, Cancer Imaging; Director, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC); Peter MacCallum Cancer Centre, Melbourne; and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Australia

8:15AM Q & A

8:17AM *Total-Body PSMA-PET vs. Short-Axial Field-of-View Conventional PSMA-PET in Patients with Biochemical Recurrence:* Andrea Di Giorgio, MD, Nuclear Medicine Unit - University of Bologna, and University of Bologna Medical Center, Italy

8:27AM Q & A

8:29AM *Micro-Ultrasound in Prostate Cancer: Role in Biopsy-Naive Patients, Decisions to Biopsy, and Active Surveillance:* Adam Kinnaird, MD, PhD, Frank and Carla Sonjonky Chair of Prostate Cancer Research, Departments of Surgery, Oncology, Radiology and Diagnostic Imaging, University of Alberta, Canada

8:39AM Q & A

8:41AM *Topic 1B: Clinical and Prognostic Implications of Cancer Visibility on Imaging*

8:41AM *Radiologic Perspective*: Sungmin Woo, MD, PhD, Associate Professor, Department of Radiology, Grossman School of Medicine, New York University

8:51AM Q & A

8:53AM *Urologic Perspective: Genomics and Natural History of MRI Invisible vs Visible Cancers: Laurence Klotz, MD*

9:03AM Q & A

9:05AM *Topic 1C: Novel and Emerging Pathological Factors in Localized and Recurrent Prostate Cancer:* Gladell P. Paner, MD, Professor of Pathology and Surgery (Urology), and Director of Genitourinary Pathology Service, University of Chicago

9:15AM Q & A

9:17AM *Topic 1D: ProQuant Update – Gleason Pattern 4 for Risk Stratification:* Andrew Vickers, PhD, Attending Research Methodologist, Memorial Sloan Kettering Cancer Center

9:27AM Q & A

9:29AM *Topic 1E: Genomic Prostate Score for Identifying Biologically Low-Risk Disease in Patients with Prostate Cancer Undergoing Active Surveillance, Surgery, or Radiotherapy:* Ericka Bagi, BSN, RN, Medical Science Liaison Director, MDxHealth, Sponsored by MDx Health.

9:35AM *Topic 1F: Integration of MRI with Histology, Genomics, and Proteomics:* Steven Raman, MD

9:45AM-10:00AM *Panel Discussion: Multiomics – Moderators and Speakers*

10:00AM-10:30AM **COFFEE BREAK**

10:30AM **SESSION II (PART 2): CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER**

Moderators:

Jane Nguyen, MD, PhD, Assistant Professor of Pathology at Case Western Reserve University/Lerner College of Medicine; Director of Genitourinary Pathology; Staff Pathologist in the Diagnostics Institute, Department of Pathology and Laboratory Medicine at Cleveland Clinic

Steven Raman, MD

Mitchell Sokoloff, MD, Professor and Chair of Urology, University of Massachusetts School of Medicine

10:30AM **Topic 2: The Future of PSMA PET Imaging:** Ashley E. Ross, MD, PhD, Associate Professor of Urology and Clinical Director, Polsky Urologic Oncology Center, Northwestern Feinberg School of Medicine. Sponsored by Blue Earth Diagnostics.

10:40AM Q & A

10:42AM **Topic 3: Beyond the Grade: Histology-Driven Risk Stratification in Prostate Cancer:** Jane Nguyen, MD, PhD

10:52AM Q & A

10:54AM **Topic 4: Year in Review - Emerging Advances in Diagnosis and Treatment:** Matthew Cooperberg, MD, MPH, Professor of Urology and Epidemiology & Biostatistics and Associate Chair for Clinical Research, Department of Urology; Helen Diller Family Chair in Urology, UCSF

11:04AM Q & A

11:06AM **Topic 5: Integration of Precision Diagnosis and Precision Treatment**

11:06AM *Topic 5A: Integrated Diagnostics (Radiogenomics) for Active Surveillance, Surgical and Radiation Treatment:* Sanoj Punnen, MD, MAS, MBA, Professor of Urology, and Vice Chair of Research, Desai Sethi Urology Institute; and Assistant Director of Clinical Research and Cancer Control Research Program Co-Lead, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami

11:16AM Q & A

11:18AM *Topic 5B: Image-Guided, Minimally-Invasive Focal Treatment: Emerging Role in Patient Management:* John Feller, MD, Chief Medical Officer, HALO Diagnostics; and Assistant Clinical Professor of Radiology, Loma Linda University School of Medicine

11:28AM Q & A

11:30AM *Topic 5C: Evolution of Surgical Data Analytics:* Archan Khandekar, MD, Assistant Professor (Urologic Oncology), University of Miami, Miller School of Medicine, Desai Sethi Urology Institute

11:40AM Q & A

11:42AM **Topic 6: Human-AI Interaction in Prostate Cancer Diagnosis:** Evis Sala, MD, PhD, FRCR, FRCP, Professor of Radiology, Università Cattolica del Sacro Cuore, Rome, Italy

11:52AM Q & A

11:54AM **Topic 7: Optimal Management of Patients Presenting with Locally Advanced Prostate Cancer in 2026*:*** Raja B. Khauli, MD, Professor of Urology, American University of Beirut Medical Center, Beirut, Lebanon; Clinical Professor of Urology, Carle Health, College of Medicine, University of Illinois in Urbana-Champaign; Adjunct Professor of Urology, University of Massachusetts Medical Center; and
Director, Middle East Prostate Cancer Consortium (MEPCC)

12:04PM Q & A

12:06PM **Topic 8: Recurrent Disease**

12:06PM *Topic 8A: Principles of Focal Salvage Treatment for Radiorecurrent Prostate Cancer – Is it Feasible?*
Giancarlo Marra, MD, Consultant Urologist and Assistant Professor, Division of Urology, AOU Citta Della Salute e Della Scienza and University of Turin, Italy

12:16PM Q & A

12:18PM *Topic 8B: NCI Working Group Recommendations on Biomedical Cancer Recurrence:* David Einstein, MD, Assistant Professor, Harvard Medical School, and Attending Physician, Beth Israel Deaconess Medical Center Genitourinary Medical Oncology Program

12:28PM Q & A

12:30PM-1:00PM *Panel Discussion: Integration of Precision Diagnosis and Treatment*

1:00PM-1:30PM **VIP NETWORKING DISCUSSION FOR SPEAKERS AND SPONSORS (BY INVITATION ONLY)**

1:30PM-2:00PM **LUNCH BREAK**

2:00PM **SESSION III: POPULATION OF MEN WITH ADVANCED PROSTATE CANCER**

Moderators:

Steven Eric Finkelstein, MD, DABR, FACRO, National Director of the Center of Advanced Radiation Excellence (CARE) and Director Radiation Oncology Research, Associated Medical Professionals/ US Urology Partners, Chair of Board, The Luther Brady Foundation of the American College of Radiation Oncology (ACRO), Board of Chancellors, American College of Radiation Oncology (ACRO)

Raluca Mititelu, MD, PhD, Lecturer, Carol Davila University of Medicine and Pharmacy, Bucharest; and Clinic of Nuclear Medicine, Central Military Emergency University Hospital, Bucharest, Romania

David Nanus, MD, Mark W. Pasmantier Professor of Hematology and Medical Oncology in Medicine, and Director of the New York-Presbyterian Hospital – Weill Cornell Medicine Healthcare System Cancer Program

2:05PM **Topic 1: Treatment for Advanced Prostate Cancer, including Oligometastatic and Systemic Disease**

2:05PM *Topic 1A: Best Practices for Clinical Trials in Patients with Advanced Prostate Cancer: Recommendations of the Prostate Cancer Working Group 4*: David Nanus, MD

2:15PM Q & A

2:17PM *Topic 1B: The Earlier Use of Radio Pharmaceuticals in Prostate Cancer:* Marc B. Garnick, MD, Director of Cancer Community Services, BIDMC; Gorman Brothers Professor of Medicine at Harvard Medical School; and Editor in Chief, *Harvard Medical School Prostate Disease Report*

2:27PM Q & A

2:29PM *Topic 1C: AI and Sequencing of Treatment:* Arnulf Stenzl, MD, Professor and Chairman, Department of Urology, University of Tuebingen, Germany; Secretary General Adjunct – European Association of Urology; and Member, European Cancer Organization (ECO) Board of Directors

2:39PM Q & A

2:41PM-3:10PM *Fireside Chat: Building Novel Approaches Combining Immunotherapy and Radiation in Prostate Cancer and Beyond:* Steven E. Finkelstein, MD, and Paul Peter Tak, MD, PhD, FMedSci, President and CEO, Candel Therapeutics

3:10PM-3:40PM *Panel Discussion: Standard and Emerging Treatment*

3:40PM-4:10PM **COFFEE BREAK**

4:10PM **Topic 2: Molecular Imaging and Theranostics**

Guest Moderator: Akram Al-Ibraheem, MD, Chairman, Department of Nuclear Medicine & PET/CT; Director, Nuclear Medicine Training Programs; and Head, Thyroid Cancer Multidisciplinary Team, King Hussein Cancer Center; President, Asia-Oceania Federation of Nuclear Medicine & Biology (AOFNMB); and President, Jordanian Society of Nuclear Medicine (JOSNM), Amman, Jordan

4:10PM *Topic 2A: PSMA-PET Metrics for Outcome Prediction in Patients with mCRPC:* Sungmin Woo, MD, PhD

4:20PM Q & A

4:22PM *Topic 2B: Integration of Molecular Imaging and Treatment:* Andrei Iagaru, MD, Professor of Radiology and Chief, Division of Nuclear Medicine and Molecular Imaging; and Co-Director, PET-MRI Research Program, Stanford University

4:32PM Q & A

4:34PM *Topic 2C: Response Assessment with PSMA PET: Where We Stand and What Can be Achieved?* Vikas Prasad, MD, PhD, Associate Professor of Radiology, Director of Clinical Theranostics, Center for Clinical Theranostics Research, Division of Nuclear Medicine, Mallinckrodt Institute of Radiology; and Co-Chair, Theranostics Program, Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri

4:44PM Q & A

4:46PM *Panel Discussion: Molecular Imaging and Theranostics*
5:00PM-

5:00PM-5:30PM **General Discussion**

5:30PM-6:00PM **VIP NETWORKING DISCUSSION FOR SPEAKERS AND SPONSORS (BY INVITATION ONLY)**

THURSDAY, OCTOBER 8, 2026

8:00AM **SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF IMAGE-TARGETED, MINIMALLY INVASIVE TREATMENT: Multimodality Diagnostics for Improved Target Definition, Patient Selection, Monitoring & Outcomes**

Moderators:

David Albala, MD, Chief of Urology, Crouse Hospital in Syracuse, New York

Mitchell Sokoloff, MD, Professor and Chair of Urology, University of Massachusetts School of Medicine

Giovanni Lughezzani, MD, Staff Physician, Department of Urology, Humanitas Clinical and Research Hospital, Rozzano (MI), and Associate Professor, Humanitas University, Milan, Italy

Stephen Zappala, MD, Clinical Assistant Professor, Department of Urology, Tufts University School of Medicine

8:10AM **Topic 1: Overview of Focal Treatment:** Mark Emberton, MD

8:20AM **Topic 2: Current Clinical Trials**

8:20AM *Urologic Perspective: Clinical Trials in Focal Treatment at NIH and Emerging Role of Intraprostatic Drug Delivery:* Peter Pinto, MD, National Institutes of Health, Director of the Urologic Oncology Fellowship Program at the National Cancer Institute

8:30AM Q & A

8:32AM *Radiologic Perspective: Multicentre Trials on Focal Therapy:* Jurgen Futterer, MD, PhD, Interventional Radiologist, Professor of Image-guided Interventional Oncology, Radboud University Medical Center, Nijmegen; and Professor, Robotics and Mechanics Group, University of Twente, The Netherlands

8:42AM Q & A

8:44AM **Topic 3: AI and Focal Treatment**

8:44AM *AI Plus Quantitative MRI for Incisionless Surgery - MRI-Guided Robotic Prostate Ablation: A Look at the Future of Medicine*? Victoria Bird, MD, President and Founder of Urologic Integrated Care, Gainesville, FLA; Staff Urologic Surgeon, HCA Florida North Florida Hospital; CEO, Urology Division, Research Group, National Medical Association; and Former Affiliate Professor of Engineering, Biomedical Engineering, College of Engineering, and Former Assistant Professor, Department of Urology, College of Medicine, University of Florida

8:54AM Q & A

8:56AM *Multi-Modal AI:* Rakesh Shiradkar, PhD, Assistant Professor, Biomedical Engineering and Informatics, Indiana University Indianapolis, Adjunct Assistant Professor, Radiology & Imaging Sciences, Pathology & Lab Medicine, Urology & Associate Member, IU Simon Comprehensive Cancer Center, Indiana University School of Medicine

9:06AM Q & A

9:08AM **Topic 4: Current State of Irreversible Electroporation (IRE) and Imaging in Prostate Cancer Focal Therapy**

Professor Phillip Stricker M.B., B.S (N.S.W.) (Hons), F.R.A.C.S. AO, Conjoint Professor, UNSW and Western Sydney University; Chairman, Department of Urology, St Vincent's Campus; Director, St Vincent's Prostate Cancer Research Centre; and Emeritus Fellow Garvan Institute

9:18AM Q & A

9:20AM **Topic 5: Is Focal Treatment Appropriate for High-Risk Prostate Cancer?**

Xiaosong Meng, MD, PhD, Dedman Family Scholar in Clinical Care, Assistant Professor, Department of Urology, UT Southwestern Medical Center

9:30AM Q & A

9:32AM **Topic 6: Comparative Analysis and Clinical Utility of the Current Modalities in Therapeutic Ablation for Prostate Cancer**

Alessandro Marquis, MD, FEBU, Urology Clinic, Department of Surgical Sciences, Molinette Hospital and University of Turin

9:42AM Q & A

9:44AM-10:20AM *Panel Discussion*

10:20AM-10:40AM **COFFEE BREAK**

10:40AM **Topic 7: Addressing Fundamental Challenges in Clinical Evaluation, Acceptance and Adoption of Image-Targeted Treatment- Perspective from the AdMeTech Foundation's International Working Group**

10:40AM *Review and Update – Imaging for Improving Post-Ablation Assessment and Developing Short-Term Patient Outcomes:* Faina Shtern, MD

10:50AM *ACR-AdMeTech PI-MAPS Project Partnership - ACR Perspective:* Etta Pisano, MD, FACR, FSBI, Chief Research Officer of the American College of Radiology; Adjunct Professor of Radiology, University of Pennsylvania and University of North Carolina at Chapel Hill

11:00AM Q & A

11:02AM *Current Approaches to MRI Reporting After Focal Treatment:* Daniel Margolis, MD, Associate Professor of Radiology, Director, Prostate MRI, and Chair, Weill Cornell Institutional Review Board, Weill Cornell Medical College, Cornell University

11:12AM Q & A

11:14AM *The Ablation Site Imaging (AIM) Multicenter Diagnostic Accuracy Study of MRI After Focal Therapy:* Alexander Light, MBBS, MRCS, NIHR Doctoral Fellow and Urology Registrar, Imperial Prostate, Imperial College London

11:24AM Q & A

11:26AM *A New Scoring System for PSMA Imaging and PSMA/MRI Integration for Patient Evaluation after Focal Treatment: Development and Preliminary Data:* Giovanni Lughezzani, MD

11:36AM Q & A

11:38AM-12:00PM **Panel on MRI Reporting After Partial Ablation and Scoring System (PI-MAPS) – Rationale, Background, & Recommendations:**

Francesco Giganti, MD, PhD, Associate Professor of Radiology, Faculty of Medical Sciences, University College London, and Honorary Consultant Radiologist, University College London Hospitals

Sangeet Ghai, MD, Professor and Trachtenberg Haque Chair in Image Guided Prostate Therapy Research, Director of Research, Joint Department of Medical Imaging, University Health Network – Mt Sinai Hospital – Women's College Hospital, University of Toronto, Canada

Daniel Margolis, MD

12:00PM-12:30PM **Panel on Molecular Imaging After Focal Treatment – Rationale, Background, Emerging Data and Next Steps:** Andrei Iagaru, MD; Irene Burger, MD, Head of Nuclear Medicine, Kantonsspital Baden, Baden Switzerland; Attending Nuclear Medicine, University Hospital Zurich, Switzerland; and Andrea Di Giorgio, MD

12:30PM-1:00PM **GENERAL DISCUSSION**

1:00PM-1:30PM **VIP NETWORKING DISCUSSION FOR SPEAKERS AND SPONSORS (BY INVITATION ONLY)**

1:30PM-2:00PM **LUNCH BREAK**

2:00PM **KEYNOTE PRESENTATION**: **We Still Don't Understand the Prostate Cancer Genome: Why Not?** Paul Boutros, PhD, MBA

2:15PM Q & A

2:30PM-3:00PM **PRESENTATION OF WINNING ABSTRACTS**

FIRST PLACE (TIE)

MRI Visibility Stratifies Risk of Grade Group Progression and Treatment Initiation in Prostate Cancer Active Surveillance: Bhavesh H. Patel, MD, David Geffen School of Medicine at UCLA

Agreement and Prediction of Response of 18F-rhPSMA-7.3 (Flotufolastat) PET vs. Post-Therapy Scintigraphy to 177Lu-PSMA Radioligand Therapy in APMR Prostate Cancer: Sonia Grigorascu, Department of Nuclear Medicine, Technical University of Munich

PSMA PET/CT and MRI for Determining Focal Therapy Eligibility in Patients with Prostate Cancer: Cohort Study with Histopathologic Validation: Zahra Mohammadigoldar, MD, Postdoc Research Fellow, Department of Radiological Sciences, David Geffen School of Medicine at UCLA

SECOND PLACE - *Diagnostic Performance of the IsoPSA Assay for Detection of High-Grade Prostate Cancer in Men with Total PSA 4–10 ng/mL Stratified by Pre-Biopsy MRI Status: No MRI and Non-Directive MRI (PI-RADS 1–3):* Mark Stovsky, MD, MBA, FACS, Cleveland Diagnostics, Inc.

THIRD PLACE (TIE)

AI at the Tumor Board: Benchmarking Three Mainstream Chatbots Against Mirrors of Medicine Uro-Oncology Experts: Anthony Mina, MD, MPH, Holy Spirit University of Kaslik, Lebanon

Initial Single-Center Experience with MRI-Guided TULSA-Pro for Localized Prostate Cancer: Early Oncologic Outcomes and Learning Curve: Andrea Lopez Sanmiguel, Yale School of Medicine

FOURTH PLACE - *Impact of Clinical Factors on 18F-Piflufolastat and 18F-Flotufolastat Detection Rates in Participants with Recurrent Prostate Cancer Post-prostatectomy: Results from an Intra-patient Head-to-head Phase 4 Study*: Jack R. Andrews, MD, Blue Earth Diagnostics & Mayo Clinic

3:00PM-4:00PM **GENERAL DISCUSSION**

4:00PM **ADJOURN**